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Conclusion. Radiation treatment achieved an excellent local control rate in this patient’s subgroup. This treatment must be
considered as a valid option to treat these patients, despite the high incidence of distal failure.
http://dx.doi.org/10.1016/j.rpor.2013.03.517
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Objective. Our objective is to determine the duration of clinical and radiological stabilization after PSA progression in chemother-
apy naïve mCRPC patients treated with AA, as well as analyzing its safety proﬁle in our series.
Material and methods. Retrospective analysis approved by our institution’s Ethical Committee of Clinical Investigation. 14 patients
with mCRPC who had not received prior chemotherapy in treatment with AA (1 g/24h) and prednisone (5mg/12h) have been
studied. Statistical analysis has been carried out with SPSS® version 15.
Results. Patient mean age is 75 (range 52–85), with 50% of patients having a pre-AA ECOG score ≥2. Mean treatment duration
time has been 9 months (2–12 months). PSA response, deﬁned as a 50% or higher decrease from pretreatment baseline PSA, was
observed in 75% of the patients. With a 12 month follow-up, we ﬁnd that: only 1 patient has progressed (deﬁned as clinical, radio-
logical and PSA progression). 7 patients (50%) present clinical, radiological and PSA stability. 7 patients present PSA progression,
of which 3 also associate radiological progression, 1 clinical progression and 1 with both clinical and radiological progression as
well. Treatment was suspended in 3 patients (21.4%), 1 due to PSA and radiological progression, 1 due to PSA, radiological and
clinical progression and 1 exitus due to tumor progression. In terms of treatment tolerance, no patients have presented neither
clinical nor hematological toxicity.
Conclusion. Treatment with AA in mCPCR chemo naïve patients is safe and very well tolerated, which is important considering
that most of the patients in our series were elderly patients, with average performance status, and in most cases not suitable for
other treatment options. In current clinical practice, evaluation for treatment response in mCRPC is changing, and PSA should
no longer be considered a reliable tumor marker in these patients. In our series, we have observed clinical and/or radiological
progression in only a small number of patients, normally months after PSA progression.
http://dx.doi.org/10.1016/j.rpor.2013.03.518
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Purpose. Determine biochemical response, control and disease free survival in a series of patients with long follow-up, treated
with salvage external beam radiation therapy (EBRT), the standard treatment for biochemical recurrence (BR), after radical
prostatectomy (RP).
Material and methods. Between July 2002 and July 2010, 78 patients were treated with salvage EBRT in our center. After EBRT,
BR has been deﬁned as a value of PSA≥0.2ng/ml. All patients were treated with 3D conformed EBRT. Median dose was 66Gy
(46–74Gy). 33 patients (42.3%) received hormone therapy (HT). All patients have been followed up by PSA and digital rectal
examination.
Results. The mean age was 65.6 years (SD 5.65). The preoperative PSA was <10, 10–20 or >20 in 54.3%, 35.7% and 10% respectively.
57.7% of patients were pT2, pT3a 17.9%, pT3b 15.4% and pTx 9%. The margins were negative in 43 patients (55.8%), and positive
in 31 (40.3%). 38 patients (62.3%) had a Gleason score ≤6, 13 Gleason 7 (21.3%) and 10 Gleason 8–10 (16.4%). The median PSA pre-
EBRT was 1.17ng/ml (range 0.12–19). The median post surgical PSA was 0.09ng/ml (range 0–4.2). The median follow-up was 46
months (range 22–116). Although biochemical response was seen in 63 patients (80.7%), the overall 5-year biochemical disease-
free survival rate was 55%. Multivariate analysis showed that ECOG (p=0.01) and post surgical PSA (p=0.03) were signiﬁcant
covariates predicting for bNED. Interval from surgery to BR, Gleason score, extracapsular extension, lymphovascular invasion,
perineural extension or surgical margin involvement were not associated with BR.
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Conclusion. Although excellent rates of biochemical response (80.7%) in patients treated with salvage EBRT, biochemical failure-
free survival at 5 years was 55%. It is essential to analyze strategies such as combination with antiandrogen treatment or increase
doses to improve results with actual treatments.
http://dx.doi.org/10.1016/j.rpor.2013.03.519
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Purpose. The role of androgen-deprivation therapy (ADT) is poorly deﬁned in the era of dose-escalated radiotherapy in
intermediate-risk prostate cancer patients. The purpose of this study is to evaluate the effect of short-term androgen-deprivation
therapy on cancer control in intermediate-risk prostate cancer patients treated with high-dose radiotherapy (HDRT).
Methods and materials. The present retrospective study comprised 185 NCCN intermediate-risk prostate cancer patients at 3 insti-
tutions treated with 3-dimensional conformal RT (76Gy) from 2002 to 2010, including 40 patients receiving ADT 2–6 months
before HDRT (none of them longer than 9 months). We deﬁned biochemical failure according to the Phoenix deﬁnition of bio-
chemical free survival (BFS). The Kaplan–Meier method and Log-rank test was used to estimate the BFS and overall survival (OS).
Cox proportion hazards regression model were performed.
Results. The minimum follow-up was 24 months, and the median follow-up was 64.6 months. For ADT patients vs. no ADT
patients, the 7-year BFS rate was 96% vs. 88% (p=0.124) and the 7-year OS rate was 92% vs. 91% (p=0.373). On Cox proportion
hazards regression model, after adjusting for pre-treatment PSA, Gleason score and T stage, the addition of ADT to HDRT did
not reveal a signiﬁcant effect on BFS (HR, 0.176; 95% CI, 0.023–1.330; p=0.092). Gleason score 7=4+3 was signiﬁcantly associated
with BFS (HR, 3.869; 95% CI, 1.267–11.813; p=0.018) compared with Gleason score ≤6. The 7-year BFS rate in Gleason 7=4+3 vs.
Gleason ≤6 was 75% vs. 94% respectively (p=0.03).
Conclusion. The addition of ADT did not signiﬁcantly improve BFS survival in intermediate-risk prostate cancer patients. The
result of this study requires testing in prospective randomized trials.
http://dx.doi.org/10.1016/j.rpor.2013.03.520
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Introduction. Dose escalation with radiotherapy is recommended in intermediate risk and high risk prostate cancer. Prostate
cancer also beneﬁts from hypofractionation schemes, according to the linear quadratic model due to its low alpha/beta.
Purpose. To analyze acute toxicity secondary to radical treatment of high and intermediate risk prostate adenocarcinoma using
VMAT with simultaneous integrated boost technique.
Material and methods. Between January 2011 and December 2012, 32 patients were treated in our department, using VMAT and
simultaneous integrated boost. D’Amico criteria were used to classify patients into risk groups. Radiation scheme used was 33
sessions of 2.25Gy (total dose 74.25Gy) to the prostate, 1.8Gy per fraction to seminal vesicles, and 1.64Gy per fraction to the pelvis
if the estimated risk of affection was greater than 15%. Daily Image-guided “Cone Beam” was performed. We hereby present a
descriptive analysis of the patients and analysis of acute toxicity (RTOG toxicity scale).
Results. Mean age was 69.24 years (60–78), intermediate 5 patients (15.6%), high risk 25 patients (78.1%). All patients received
complete androgen blockade. Volumes of treatment in 1 patient (3.1%) only prostate, 20 patients (62.5%) prostate +vesicles, and 11
patients (34.4%) prostate +pelvis + vesicles.Dosimetric values (median) of thePTV (planning target volume). ProstateD2%79.16Gy,
D50% 76.29Gy, D98% 71.3Gy. PTV prostate +vesicles: D2% 78.52Gy, D50% 73.69Gy, D98% 58.7Gy. PTV pelvis +prostate +vesicles:
D2% 77.36Gy, D50% 55.97Gy, D98% 51.14Gy. Maximum toxicity recorded was grade 2. Urinary G2, 2 patients (6.3%); frequency
G2, 8 patients (25%); dysuria G2, 4 patients (12.5%), asthenia G1, 5 patients (15.6%); ﬂushes G2, 2 patients (6.3%); proctitis G2, 1
patient (3.1%).
Conclusions. Treatment of prostate cancer with simultaneous integrated boost with VMAT provides optimal coverage to different
target volumes while acute toxicity remains acceptable.
http://dx.doi.org/10.1016/j.rpor.2013.03.521
